BIOFABICS
Develops customizable 3D biotissue analogues and organ-on-chip devices using biofabrication and additive manufacturing for drug discovery and personalized medicine.
- CEO / Founder
- Pedro Costa
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $487K
- Latest Round
- Pre-Seed
- Key Investors
- Startup Braga
Technology & Products
Key Products
Customizable, truly 3D organ-on-chip devices for drug discovery and personalized medicine; 3D biotissue analogues for research and drug testing.
Technological Advantage
Proprietary expertise in integrating multiple advanced technologies (biofabrication, microfluidics, organs-on-chips) validated through scientific publications and patents.
Differentiation
Value Proposition
Provides more accurate and reliable 3D tissue and organ models compared to conventional 2D cultures, enabling better drug testing and personalized treatment development.
How They Differentiate
Focuses on fully customizable 3D biotissue analogues and organ-on-chip devices with an interdisciplinary technology stack, unlike competitors that may offer more standardized bioprinting solutions.
Market & Competition
Target Customers
Pharmaceutical companies, research labs, academic institutions
Industry Verticals
Biotechnology; Pharmaceuticals; Medical Research
Competitors
3D Biotek, LLC; Allevi by 3D Systems; Aspect Biosystems
Growth & Milestones
Major Milestones
Founded in 2017; Received Horizon 2020 funding under Marie Sklodowska-Curie programme; CEO Pedro Costa awarded 2014 Translation Award (European Society for Biomaterials) and 2016 Young Investigator Award (International Society for Biofabrication)